DICE Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
“In preclinical head-to-head studies of S011806 and COSENTYX, S011806 was able to selectively inhibit both IL-17AA and IL-17AF isoforms, while sparing the IL-17FF isoform, consistent with the inhibition profile of COSENTYX. Furthermore, we have shown that S011806 matched the anti-inflammatory activity of an anti-IL-17 mAb in a well-established animal model.” (Page 5) Read the full document
Dice Therapeutics, Inc., formerly Dice Molecules Holdings LLC, is a biopharmaceutical company. The Company leverages its technology platform to build a pipeline of oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. It focuses on developing oral therapeutics against well-validated targets in immunology.
Company Website: https://www.dicetherapeutics.com